Pyrojas Inc.
Biotechnology company developing immune therapies that use patient-derived whole tumor cells and modular cell-engineering to generate durable anti-tumor T cell memory. Work emphasizes autologous whole-tumor-cell vaccine engineering, rapid non-viral cell engineering, tumor microenvironment modulation modules for adoptive cell therapies, preclinical translation, and licensing collaborations with academic and industry partners.
Industries
N/A
Products
Patient-derived whole tumor cell vaccine (autologous whole-cell vaccine)
Autologous vaccine approach using a patient’s entire tumor as the immunogen to present the full antigenic landscape and induce diversified T cell responses.
Modular T cell function boosting module for adoptive cell therapies
A plug-in module engineered to be integrated into adoptive cell therapies that secretes peptides to neutralize suppressive signals in the tumor microenvironment and enhance persistence and cytotoxicity.
Patient-derived whole tumor cell vaccine (autologous whole-cell vaccine)
Autologous vaccine approach using a patient’s entire tumor as the immunogen to present the full antigenic landscape and induce diversified T cell responses.
Modular T cell function boosting module for adoptive cell therapies
A plug-in module engineered to be integrated into adoptive cell therapies that secretes peptides to neutralize suppressive signals in the tumor microenvironment and enhance persistence and cytotoxicity.
Services
Licensing of modular cell-engineering components
Commercial licensing of integration-ready modules that enhance T cell function in suppressive tumor microenvironments for incorporation into adoptive cell therapy pipelines.
Licensing of modular cell-engineering components
Commercial licensing of integration-ready modules that enhance T cell function in suppressive tumor microenvironments for incorporation into adoptive cell therapy pipelines.
Expertise Areas
- Autologous cancer vaccine development
- Tumor immunology and T cell memory
- Cell engineering (non-viral methods)
- Tumor microenvironment modulation
Key Technologies
- Autologous whole-tumor-cell vaccine
- Non-viral cell engineering
- Adjuvant-enhanced vaccine formulation
- Engineered secretion of immunomodulatory peptides